US plans to cap H-1B visas to deter India's data storage normsThe United States has told India it is considering caps on H-1B work visas for nations that force foreign companies to store data locally, three sources with knowledge of the matter told Reuters, widening the two countries' row over tariffs and trade. The plan to restrict the popular H-1B visa programme, under which skilled foreign workers are brought to the United States each year, comes days ahead of U.S. Secretary of...

How a host of corporates are partnering with Indian farmers for a win-win yield and lessening agrarian distress.

The proposal to reimburse people affected by faulty medical devices will be taken up at the Drug Technical Advisory Board (DTAB), scheduled a week from today.

The decision was taken after drug makers filed a petition, saying that these drugs were being manufactured since 1988. They cited the SC's earlier relief to 15 manufacturers on the bases of the similar grounds, saying that they should also be exempted from the ban.

As the industry is trying to digest the development, not totally unexpected though, there are fresh concerns on what could come next as the ministry-appointed Prof Kokate Expert committee had discussed banning many more FDC drugs.

India reportedly boasts around 2,000 FDCs, four times more that what's available in the US.

The FDC medicines are two or more drugs contained in a single dosage form. The health ministry says it took the decision to ban these drugs after the Drugs Technical Advisory Board suggested these drugs might pose a risk to human beings.

6,000 medicine brands worth about Rs 2,500-odd crore are likely to be banned soon.

The drugs under question are 349 fixed dose combinations drugs containing two or more active pharmaceutical ingredients in a fixed dosage ratio, which are floating in the Rs 1.1-lakh crore Indian drug market.